Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 730 full-time employees. The firm's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for MLAB. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: MLAB is a Buy candidate.
MLAB stock price ended at $100.79 on 星期三, after dropping 2.80%
On the latest trading day May 13, 2026, the stock price of MLAB fell by 2.80%, dropping from $102.93 to $100.79. During the session, the stock saw a volatility of 3.57%, with prices oscillating between a daily low of $100.09 and a high of $103.66. On the latest trading day, the trading volume for MLAB rose by 57.2K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 135.6K shares were traded, with a market value of approximately $556.3M.